Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-300
Closed -$19.5K 7548
2025
Q2
$19.5K Buy
+300
New +$18K ﹤0.01% 6182
2023
Q1
Sell
-175,500
Closed -$13.1M 6939
2022
Q4
$13.1M Buy
+175,500
New +$12.5M ﹤0.01% 2021
2021
Q4
Sell
-10,500
Closed -$775K 6778
2021
Q3
$775K Buy
+10,500
New +$787K ﹤0.01% 4480
2020
Q4
Sell
-3,300
Closed -$218K 5749
2020
Q3
$218K Buy
+3,300
New +$209K ﹤0.01% 4319
2019
Q2
Sell
-148,300
Closed -$7.18M 5855
2019
Q1
$7.18M Buy
+148,300
New +$6.69M ﹤0.01% 2314

Other funds holding HOLX

JP Morgan Chase's HOLX Position: Q1 2026 in Review

JP Morgan Chase increased its Hologic (HOLX) stake by 96% in Q1 2026, buying an estimated $122M and bringing the position to 3,301,493 shares worth $249M. The position accounts for 0.02% of the portfolio, ranked #606.

JP Morgan Chase first reported a position in HOLX in Q2 2013 and has held it in 52 quarters since. The position peaked at $271M in Q2 2023. 704 funds tracked by Wall St. Rank hold HOLX as of Q1 2026.

  • JP Morgan Chase held 3,301,493 shares of Hologic worth $249M as of Q1 2026.
  • JP Morgan Chase bought 1,618,203 Hologic shares in Q1 2026, an estimated $122M.
  • Hologic made up 0.02% of JP Morgan Chase's portfolio in Q1 2026, its #606 holding.
  • JP Morgan Chase first reported a position in Hologic in Q2 2013 and has held it in 52 quarters since.
  • JP Morgan Chase's Hologic position peaked at $271M in Q2 2023.
  • 704 funds tracked by Wall St. Rank held Hologic as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.